Ivermectin for preventing and treating COVID-19

This study reported results for development of COVID-19 symptoms (but not confirmed SARS-CoV-2 infection) and unwanted events, but in a way that we could not include in our analyses. This study did not look at hospital admissions.Main results explainedMain authors of the review, Maria Popp and Stephanie Weibel said: “The lack of good quality evidence on efficacy and safety of ivermectin arises from a study pool that consists mainly of small, insufficiently powered RCTs with overall limited quality regarding study design, conduct, and reporting. Current evidence does not support using ivermectin for treating o r preventing of COVID-19 unless they are part of well-designed randomized trials.” What are the limitations of the evidence?Confidence in the evidence is very low because the authors could only include 14 studies with few participants and few events, such as deaths or need for ventilation. The methods differed between studies, and they did not report everything they were interested in, such as quality of life.  How up to date is this evidence?The evidence is up to date to 26 May 2021.What ’s next?Evaluation of ivermectin is continuing in 31 ongoing studies; the authors will update this review with their results when they become available.  Read the review ' Ivermectin for preventing and treating COVID-19 'Visit the Cochrane Infectious Diseases Group websiteWednesday, July 28, 2021
Source: Cochrane News and Events - Category: Information Technology Authors: Source Type: news